Menu
Recruiting NCT06607731

Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

— Observational Bone Angioma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Collecting data from medical records.
Who it may be relevant to
Registry conditions: Bone Angioma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

Interventions

  • Other Collecting data from medical records
    Data collected: clinical data (particularly pain), biological data, imaging.

Primary outcome measures

  • Number of complications identified in data collection [Time frame: Day 1]
Secondary outcome measures (1)
  • Number of lesion identified in data collection [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne.

Exclusion criteria

  • Patients no treated by gelled alcohol sclerotherapy.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • CHU de Saint-Etienne — Saint-Priest-en-Jarez

Identifiers

NCT: NCT06607731 · IRBN312024/CHUSTE

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗